Fri, May 9, 11:11 AM (10 days ago)
**Boundless Bio, Inc. (BOLD) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated; the company is in the clinical-stage and has not yet commercialized any products. - **Profit Margins:** Operating loss of $17.341 million, with a net loss of $15.758 million for Q1 2025, compared to an operating loss of $16.883 million and a net loss of $15.430 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $14.530 million, a decrease from $15.776 million in Q1 2024. Net cash provided by investing activities was $3.060 million, down from $18.137 million in the prior year. - **Earnings Changes:** Net loss per share was $0.71 for Q1 2025, compared to $12.27 in Q1 2024, reflecting the reverse stock split. **Key Metrics and Trends:** - **R&D Expenses:** Decreased by $0.991 million, primarily due to reduced spending on the STARMAP clinical trial of BBI-825 and other development programs, offset by increased investment in the POTENTIATE clinical trial of BBI-355. - **G&A Expenses:** Increased by $1.449 million, driven by higher facilities-related costs, stock-based compensation, and public company expenses. - **Cash Position:** As of March 31, 2025, the company had $138.3 million in cash, cash equivalents, and short-term investments. The company believes this will be sufficient to fund operations into 2027. **Future Operations and Uncertainties:** - **Clinical Trials:** The company is focused on advancing its lead ecDTx, BBI-355, and expects preliminary clinical proof of concept data in the second half of 2025. The STARMAP trial for BBI-825 was discontinued. - **Funding:** The company plans to raise additional capital through equity offerings, debt financings, or other arrangements to support ongoing and planned clinical trials, preclinical studies, and potential commercialization. - **Regulatory and Market Risks:** The company faces uncertainties related to regulatory approvals, market conditions, and competition. The success of its ecDTx programs is crucial for future revenue generation. **Conclusion:** Boundless Bio, Inc. continues to invest heavily in R&D with no revenue generation, reflecting the typical financial profile of a clinical-stage biotech company. The company's financial health is supported by its cash reserves, but it faces significant uncertainties related to clinical trial outcomes, regulatory approvals, and market conditions. Future operations will depend on successful clinical trials, strategic funding, and effective management of operational and market risks.